CD68 and breast carcinoma: In a study assessing the immune infiltrate in 121 patients with stage II or III breast cancer, before and after receiving NAC, García-Martínez et al., reported that while a high number of CD3, CD4, CD68 and CD20 cells before treatment were significantly correlated with pCR after chemotherapy, mainly CD68+ cells and tumor associated macrophages were found to be associated with worse DFS and OS, especially for those with residual tumors (no pCR) [37] (Figure 3).